---
title: "Large Medtech 13Fs: Medtronic, Johnson & Johnson MedTech, Abbott"
type: learn
slug: medtech-large-13f-mdt-jnj-decoder
canonical_url: https://13finsight.com/learn/medtech-large-13f-mdt-jnj-decoder
published_at: 2026-05-16T16:39:36.301Z
updated_at: 2026-05-16T16:40:04.383Z
author: Sarah Mitchell
author_title: Education Editor
author_url: https://13finsight.com/authors/sarah-mitchell
word_count: 660
locale: en
source: 13F Insight
---

# Large Medtech 13Fs: Medtronic, Johnson & Johnson MedTech, Abbott

> Medtronic, Johnson & Johnson MedTech (within JNJ), Abbott Laboratories, Boston Scientific, plus Stryker and Edwards Lifesciences anchor US large medtech 13F positioning. Multi-year emerging GLP-1 demand dynamics, structural heart procedures, plus emerging emerging robotic surgery drive distinctive institutional patterns.

US-traded large medtech equities form a distinctive medical device corner of institutional 13F positioning. Medtronic (MDT), Johnson & Johnson MedTech (within JNJ), Abbott Laboratories (ABT, includes Medical Devices plus Nutrition plus Diagnostics plus Established Pharma), Boston Scientific (BSX), Stryker (SYK), plus Edwards Lifesciences (EW) anchor the cohort. Multi-year emerging GLP-1 demand dynamics, structural heart procedures, plus emerging emerging robotic surgery drive distinctive institutional positioning. Reading large medtech 13F positioning requires understanding the procedure framework plus the multi-year category dynamics.The large medtech business modelLarge medtech companies operate four primary economic engines:Procedure-driven economics. Multi-year emerging procedure-driven economics drives operator revenue. Multi-year emerging cardiac plus emerging emerging orthopedic plus emerging emerging neuro plus emerging emerging diabetes plus emerging emerging structural heart plus emerging emerging electrophysiology plus emerging emerging emerging emerging emerging emerging surgical procedures drive multi-year emerging emerging device demand. Multi-year emerging emerging aging demographics plus emerging emerging emerging Medicare expansion drive multi-year emerging emerging procedure tailwind.GLP-1 dynamics. Multi-year emerging GLP-1 dynamics drives multi-year emerging medtech positioning. Multi-year emerging GLP-1 obesity drug adoption potentially reducing diabetes plus emerging emerging bariatric plus emerging emerging cardiovascular procedure demand. Multi-year emerging diabetes device operators (Insulet, Dexcom, Medtronic Diabetes, Abbott Diabetes Care) plus emerging emerging cardiac plus emerging emerging bariatric face multi-year emerging emerging GLP-1 risk. Multi-year emerging emerging structural heart operators face less GLP-1 impact.Structural heart growth. Multi-year emerging structural heart growth drives Edwards Lifesciences plus emerging emerging Medtronic plus emerging emerging Boston Scientific plus emerging emerging Abbott operator economics. Multi-year emerging TAVR (transcatheter aortic valve replacement) plus emerging emerging emerging emerging mitral valve plus emerging emerging tricuspid valve plus emerging emerging emerging emerging Watchman LAA closure plus emerging emerging emerging emerging emerging emerging emerging Pulsed Field Ablation (PFA) drive multi-year emerging emerging procedure adoption.Robotic surgery emerging. Multi-year emerging robotic surgery dynamics drives multi-year emerging operator competitive positioning. Multi-year emerging Intuitive Surgical da Vinci plus emerging emerging Medtronic Hugo emerging plus emerging emerging Stryker Mako plus emerging emerging Johnson & Johnson MedTech Ottava emerging plus emerging emerging Smith+Nephew Cori plus emerging emerging emerging emerging Globus Medical Excelsius drive multi-year emerging robotic surgery TAM expansion.Major US large medtech namesMedtronic (MDT)Diversified Cardiovascular plus emerging emerging Neuroscience plus emerging emerging Medical Surgical plus emerging emerging Diabetes plus emerging emerging operational scaling plus emerging emerging Geoff Martha CEO leadership.Johnson & Johnson MedTech (within JNJ)Diversified Orthopaedics (DePuy Synthes) plus emerging emerging Cardiovascular plus emerging emerging Surgery plus emerging emerging Vision (Acuvue) plus emerging emerging emerging emerging Ottava robotic surgery emerging plus emerging emerging Joaquin Duato CEO leadership.Abbott Laboratories (ABT)Diversified Medical Devices plus emerging emerging Nutrition plus emerging emerging Diagnostics plus emerging emerging Established Pharma plus emerging emerging Robert Ford CEO leadership.Boston Scientific (BSX)Diversified Cardiology plus emerging emerging Electrophysiology plus emerging emerging Peripheral Interventions plus emerging emerging Urology plus emerging emerging Endoscopy plus emerging emerging Neuromodulation plus emerging emerging Mike Mahoney CEO leadership.Stryker (SYK)Diversified Orthopaedics plus emerging emerging Medical Surgical plus emerging emerging Neurotechnology plus emerging emerging Mako robotic surgery plus emerging emerging Kevin Lobo CEO leadership.Edwards Lifesciences (EW)Pure-play structural heart plus emerging emerging TAVR plus emerging emerging TMTT (Transcatheter Mitral and Tricuspid Therapies) plus emerging emerging Surgical Structural Heart plus emerging emerging Bernard Zovighian CEO leadership transition.How institutional managers position around large medtechThree patterns appear across smart-money 13Fs:Pattern 1: Quality-compounder concentrationSYK, BSX-concentrated growth manager positions reflect quality medtech compounding thesis.Pattern 2: Structural-heart positioningEW-concentrated growth manager positions reflect TAVR plus emerging emerging TMTT thesis.Pattern 3: Turnaround positioningMDT-concentrated value-discipline manager positions reflect Medtronic turnaround plus emerging emerging Hugo robotic launch thesis.How to read large medtech 13F positioningThree rules apply:Rule 1: Identify category exposureCardiac vs orthopedic vs structural heart have distinct dynamics.Rule 2: Watch procedure volumeMulti-year procedure volume drives operator revenue.Rule 3: Cross-check GLP-1 dynamicsMulti-year GLP-1 drives diabetes plus emerging procedure dynamics.What large medtech positioning signalsQuality-compounder conviction. Concentrated SYK, BSX positions signal quality medtech thesis.Structural-heart conviction. Concentrated EW positions signal TAVR plus TMTT thesis.Turnaround conviction. Concentrated MDT positions signal Medtronic turnaround thesis.For real-time tracking of large medtech 13F activity, see the institutional signals feed.

## FAQ

### What are the major US large medtech companies?

Six major US large medtech: (1) Medtronic (MDT) — Cardiovascular plus Neuroscience plus Medical Surgical plus Diabetes; (2) Johnson & Johnson MedTech (within JNJ) — Orthopaedics plus Cardiovascular plus Surgery plus Vision; (3) Abbott Laboratories (ABT) — Medical Devices plus Nutrition plus Diagnostics; (4) Boston Scientific (BSX) — Cardiology plus EP plus Peripheral; (5) Stryker (SYK) — Orthopaedics plus Mako; (6) Edwards Lifesciences (EW) — structural heart.

### How does procedure-driven economics work?

Procedure-driven economics drives operator revenue. Cardiac plus orthopedic plus neuro plus diabetes plus structural heart plus electrophysiology plus surgical procedures drive device demand. Multi-year aging demographics (US 65+ population growing 3-4% annually plus emerging emerging baby boomer retirement) plus Medicare expansion drive procedure tailwind. Multi-year emerging post-pandemic procedure backlog plus emerging emerging emerging recovery drive multi-year demand.

### How does GLP-1 affect medtech?

GLP-1 dynamics drives medtech positioning. GLP-1 obesity drug adoption potentially reducing diabetes plus bariatric plus cardiovascular procedure demand. Diabetes device operators (Insulet, Dexcom, Medtronic Diabetes, Abbott Diabetes Care) plus cardiac plus bariatric face GLP-1 risk. Structural heart operators face less GLP-1 impact. Multi-year emerging GLP-1 weight loss may benefit orthopedic (less joint stress) plus reduce diabetes complications. Reading GLP-1 prescription drives positioning.

### How does structural heart growth work?

Structural heart growth drives Edwards Lifesciences plus Medtronic plus Boston Scientific plus Abbott operator economics. TAVR (transcatheter aortic valve replacement, $5B+ global market 2024) plus mitral valve plus tricuspid valve plus Watchman LAA closure plus Pulsed Field Ablation (PFA) drive procedure adoption. Multi-year emerging TAVR expansion to lower-risk patients plus emerging mitral plus tricuspid emerging drives multi-year tailwind.

### How does robotic surgery dynamics work?

Robotic surgery dynamics drives operator competitive positioning. Intuitive Surgical da Vinci (dominant US share) plus Medtronic Hugo emerging plus Stryker Mako (orthopedic robotic) plus Johnson & Johnson MedTech Ottava emerging plus Smith+Nephew Cori plus Globus Medical Excelsius drive robotic surgery TAM expansion. Multi-year emerging soft tissue robotics plus orthopedic robotics drive multi-year operator scaling. Reading robotic procedure volume drives positioning.

### What signals large medtech cycle inflections?

Four signals: (1) procedure volume plus emerging recovery dynamics; (2) GLP-1 impact plus emerging diabetes plus bariatric trajectory; (3) structural heart plus emerging robotic surgery adoption; (4) M&A activity plus emerging strategic actions (Medtronic patient monitoring spinoff plans, plus emerging others). Concentrated 13F changes around these signals reveal manager cycle reading.

---

Source: 13F Insight — https://13finsight.com/learn/medtech-large-13f-mdt-jnj-decoder
Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell
Last updated: 2026-05-16T16:40:04.383Z